Seminars in Hematology
Volume 44 , Pages S7-S11 , July 2007

Current Therapeutic Approaches to Patients With Newly Diagnosed Low-Grade Non-Hodgkin’s Lymphoma

  • Stephanie A. Gregory

      Affiliations

    • Corresponding Author InformationAddress correspondence to Stephanie A. Gregory, MD, The Elodia Kehm Professor of Medicine, Director, Section of Hematology, Rush University Medical Center, Rush University, 1725 W Harrison St, Suite 834, Chicago, IL 60612-3828.

References 

  1. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004;203–220
  2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes (Non-Hodgkin’s Lymphoma Classification Project). J Clin Oncol. 1998;16:2780–2795
  3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  4. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475
  5. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol. 1993;20:75–88
  6. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin’s Lymphoma. v.2. 2006
  7. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–1459
  8. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265
  9. Kaminski MS, Coleman CN, Colby TV, et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med. 1986;104:747–756
  10. Anderson JR, Vose JM, Bierman PJ, et al. Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol. 1993;11:218–224
  11. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001
  12. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients—A study of the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1999;17:2499–2505
  13. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336–4342
  14. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–1270
  15. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood. 2001;97:101–106
  16. Colombat P, Brousse N, Morschhauser F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analyses with extended follow-up (F/Up) of 7 years. Blood. 2006;108:147a;(abstr 486)
  17. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332–2338
  18. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–4423
  19. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–1095
  20. In Focus: ECOG 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Adv Hematol Oncol. 2004;2:152
  21. Hochster HS, Weller E, Ryan T, et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol. 2004;23:556;(abstr)
  22. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106:106a;(abstr 349)
  23. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716
  24. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732
  25. Zinzani PL. Clinical experience with fludarabine in indolent non-Hodgkin’s lymphoma. Hematol J. 2004;5(suppl 1):S38–S49
  26. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: A randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol. 2003;22:564;(abstr 2269)
  27. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  28. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694–704
  29. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood. 2004;104:169a;(abstr 584)
  30. Fermé C, Vanel D, Ribrag V, Girinski T. Role of imaging to choose treatment. Cancer Imaging. 2005;5(suppl A):S113–S119
  31. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143–4149
  32. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449
  33. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696–5704
  34. Link B, Kaminiski MS, Coleman M, et al. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol. 2004;22:560;(abstr 6520)
  35. Friedberg JW, Huang J, Dillon H, et al. Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol. 2006;24:428s;(abstr 7527)
  36. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;23:4390–4398

PII: S0037-1963(07)00095-9

doi: 10.1053/j.seminhematol.2007.06.004

Seminars in Hematology
Volume 44 , Pages S7-S11 , July 2007

Article Tools